Biotech | December 06, 2021
AWS partners with Pfizer to accelerate drug development
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
It works with Pfizer to support more rapid innovation and improved clinical manufacturing operations to help develop tomorrow’s therapies
The programme will be implemented across 13 states and benefit 256 min
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
The goal for the project is the identification and optimization of anti-viral compounds.
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
The research underscores growing concern that the intersection of neurodevelopmental conditions and social disadvantage can significantly compound health risks across the life course
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
The filing is backed by positive Phase 3 results recently published in JAMA Neurology
The safety profile of the Lunsumio and Polivy combination was consistent with the known profiles of the individual study medicines
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
